TY - JOUR
T1 - Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma
AU - Hoerr, Amy L.
AU - Gao, Feng
AU - Hidalgo, Josephine
AU - Tiwari, Divya
AU - Blum, Kristie A.
AU - Mathews, Vikram
AU - Adkins, Douglas R.
AU - Blum, William
AU - Devine, Steven
AU - Vij, Ravi
AU - Goodnough, Lawrence T.
AU - Dipersio, John F.
AU - Khoury, Hanna J.
PY - 2004
Y1 - 2004
N2 - Purpose: To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL). Patients and Methods: Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation. Results: R was administered a median of 3 months before autologous transplantation. When compared to the nonrituximab group, R patients were older (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P = .001). Pretransplantation R did not affect stem-cell mobilization, post-transplantation early complications, duration of hospitalization, or mortality rates at days 30 and 100. In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL. Conclusion: In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.
AB - Purpose: To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL). Patients and Methods: Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation. Results: R was administered a median of 3 months before autologous transplantation. When compared to the nonrituximab group, R patients were older (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P = .001). Pretransplantation R did not affect stem-cell mobilization, post-transplantation early complications, duration of hospitalization, or mortality rates at days 30 and 100. In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL. Conclusion: In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.
UR - http://www.scopus.com/inward/record.url?scp=16544369964&partnerID=8YFLogxK
U2 - 10.1200/JCO.2004.05.035
DO - 10.1200/JCO.2004.05.035
M3 - Article
C2 - 15542807
AN - SCOPUS:16544369964
SN - 0732-183X
VL - 22
SP - 4561
EP - 4566
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 22
ER -